M&A landscape is tilting away from late-stage buys and toward a platform strategy: analysts

The times are changing in the biopharma industry—and it’s happening fast. From 2019 to 2021, for example, total investment in biotechs nearly doubled, which helps explain why the average premium for purchasing biotech assets increased from 51% in 2018 to 71% last year.